Abstract
Surgical site infections (SSIs) are the third most common nosocomial infection. An antimicrobial suture was approved recently by the FDA and its use to control SSIs is supported by the high incidence of SSIs localized to the incision, the juxtaposition of sutures with incisional wounds and efficacy in preclinical models of SSIs. However, the active agent in the suture, triclosan, has associated liabilities including limited coverage for certain SSI pathogens, ubiquitous use in consumer products and the potential for resistance. Therefore, substitution of more appropriate active agents in antimicrobial sutures is highly warranted. We have developed small nonpeptidic mimics of host defense proteins (HDP) as antimicrobial agents and examined their suitability versus triclosan as active agents for antimicrobial sutures.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call